Biodel Inc. (NASDAQ:ALBO) – Investment analysts at Wedbush lifted their Q3 2017 earnings per share estimates for Biodel in a research note issued to investors on Monday. Wedbush analyst L. Moussatos now anticipates that the biopharmaceutical company will earn ($0.76) per share for the quarter, up from their previous forecast of ($0.89). Wedbush has a “Outperform” rating and a $58.00 price objective on the stock. Wedbush also issued estimates for Biodel’s Q4 2017 earnings at ($0.77) EPS, FY2017 earnings at ($3.38) EPS, Q1 2018 earnings at ($0.76) EPS, Q2 2018 earnings at ($0.76) EPS, Q3 2018 earnings at ($0.77) EPS, Q4 2018 earnings at ($0.77) EPS, FY2018 earnings at ($3.06) EPS and FY2019 earnings at ($3.06) EPS.

A number of other research analysts have also weighed in on ALBO. Zacks Investment Research lowered Biodel from a “hold” rating to a “sell” rating in a research note on Tuesday, May 23rd. Needham & Company LLC initiated coverage on Biodel in a research note on Tuesday, July 18th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Cowen and Company initiated coverage on Biodel in a research note on Wednesday, August 16th. They set an “outperform” rating on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Biodel currently has an average rating of “Buy” and an average price target of $40.33.

WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at

Shares of Biodel (ALBO) opened at 23.35 on Thursday. The firm’s 50-day moving average price is $23.81 and its 200 day moving average price is $22.54. Biodel has a 1-year low of $11.70 and a 1-year high of $37.69. The firm’s market cap is $207.39 million.

Biodel (NASDAQ:ALBO) last posted its earnings results on Monday, August 21st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.02).

A hedge fund recently raised its stake in Biodel stock. Renaissance Technologies LLC grew its holdings in shares of Biodel Inc. (NASDAQ:ALBO) by 0.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 149,632 shares of the biopharmaceutical company’s stock after purchasing an additional 794 shares during the quarter. Renaissance Technologies LLC’s holdings in Biodel were worth $3,591,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 27.36% of the company’s stock.

About Biodel

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Earnings History and Estimates for Biodel (NASDAQ:ALBO)

Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with's FREE daily email newsletter.